News
ACG Packaging Materials Joins WEF Global Lighthouse Network
ACG Packaging Materials has announced that its Shirwal manufacturing facility has been formally designated a global Lighthouse and admitted into the World Economic Forum’s (WEF) Global Lighthouse Network (GLN). With this recognition, ACG becomes the world’s first pharmaceutical packaging...
News
Janumet and Weight Loss: Evidence, Expectations, and Safe Use
For people with type 2 diabetes, medication choices often balance glucose control with side effects, weight impact, and practical access. Combination therapies such as sitagliptin/metformin (brand: Janumet) sit within that balance. They are used to improve glycemic control and...
Business & Industry
Halo Pharma Emerges as the North American Drug Product CDMO
Halo Pharma becomes dedicated North American drug product CDMO after emerging as a standalone contract development and manufacturing organization focused exclusively on drug product services in North America. The transition follows SK Capital Partners’ decision to divest the active...
News
Vetter Pharma to Build New Manufacturing Site in Germany
Vetter Pharma manufacturing site in Germany plans have been confirmed as the pharmaceutical service provider moves forward with building a new commercial production facility in the Saarland region of southwest Germany. The company said construction is scheduled to begin...
Business & Industry
Drugmakers Turn to AI To Speed Up Trials and Submissions
Drugmakers turn to AI as a practical way to reduce delays in clinical trials and regulatory submissions, even as artificial intelligence has yet to consistently deliver breakthrough drug molecules, industry executives said at the JP Morgan Healthcare Conference.
Executives from...
Business & Industry
Seamless Therapeutics and Eli Lilly Hearing Loss Collaboration
Seamless Therapeutics has entered a global research collaboration and licensing agreement with Eli Lilly and Company under the Seamless Therapeutics Eli Lilly hearing loss collaboration, focused on developing programmable recombinase-based genetic medicines for hearing loss.
The collaboration will unite Seamless...
Business & Industry
AstraZeneca CSPC Weight-Loss Deal Reaches $18.5 Billion
AstraZeneca has agreed to license experimental obesity and metabolic disease drugs from China’s CSPC Pharmaceutical Group under the AstraZeneca CSPC weight-loss deal, with total potential payments reaching $18.5 billion.
The agreement includes $1.2 billion paid upfront, with up to $17.3...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read